Royalty Pharma (RPRX) investor relations material

Executive summary

• Achieved 14% year-over-year growth in Royalty Receipts to $768 million in Q2 2026, with strong business momentum and robust portfolio expansion driven by Tremfya, Voranigo, Imdelltra, and Evrysdi.

• Portfolio Receipts grew 6% to $773 million in Q2 2026, exceeding guidance and reflecting lower milestones and other contractual receipts.

• Deployed over $1.1 billion in royalty acquisitions YTD, including a $425 million royalty on AstraZeneca's cliramitug, and returned $370 million to shareholders via dividends and buybacks in H1.

• Raised full-year 2026 guidance for the second consecutive quarter, reflecting strong momentum and portfolio expansion.

• Maintained a well-balanced, low-risk portfolio anchored by approved products and a high development-stage success rate.

Financial highlights

• Royalty Receipts grew 14% year-over-year to $768 million in Q2 2026; Portfolio Receipts up 6% to $773 million.

• Adjusted EBITDA increased 16% year-over-year to $736 million in Q2 2026, with Portfolio Cash Flow margin at 95%.

• Return on invested capital was 14.2% and return on invested equity 20.1% for the last 12 months.

• Weighted average share count declined by 1% to 557 million due to buybacks.

• Cash and equivalents: $812 million; investment-grade debt: $9.2 billion (12-year avg. duration).

Outlook and guidance

• 2026 Portfolio Receipts guidance raised to $3,400–$3,500 million, with expected Royalty Receipts growth of 7–10%.

• Guidance reflects expected headwinds from PROMACTA LOE, biosimilar Tysabri launch, and IRA impact.

• Operating/professional costs expected at 5.5–6.5% of Portfolio Receipts; interest paid $350–$360 million.

• Milestones and other contractual receipts expected to decrease to ~$60 million in 2026.

• Guidance assumes no major adverse events or FX changes and excludes future transactions.